search
Back to results

Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer (ARMANI)

Primary Purpose

Colorectal Liver Metastasis

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Resection of colorectal liver metastases
Sponsored by
Technische Universität Dresden
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Liver Metastasis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Colorectal cancer with RAS mutation (KRAS or NRAS)
  • Colorectal liver metastases (single or multiple)
  • Planned R0 resection of liver metastases (and primary tumor, if present)
  • Anatomical and non-anatomical liver resection technically feasible
  • Male and female patients, age ≥ 18 years
  • Written informed consent

Exclusion Criteria:

  • Extrahepatic metastases
  • Planned staged liver resection (e.g. two-stage hepatectomy)
  • Diagnosis of another cancer < 5 years prior to randomization Exceptions: curatively treated in situ cervical cancer, curatively resected non-melanoma skin cancer
  • Expected lack of compliance
  • Addiction or other illnesses which do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences

Sites / Locations

  • Department of Surgery at the University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg UniversityRecruiting
  • Department of Gastrointestinal-, Thoracic and Vascular Surgery University Hospital Carl Gustav Carus Technische Universität DresdenRecruiting
  • Department of General, Visceral and Vascular Surgery, Charité, University Medicine Berlin, Campus Benjamin Franklin BerlinRecruiting
  • Clinic and Polyclinic for General, Visceral, Thoracic and Vascular Surgery, University Hospital BonnRecruiting
  • Surgical Clinic, Municipal Hospital Braunschweig gGmbHRecruiting
  • Cancer Center, Helios Amper-Hospital DachauRecruiting
  • Clinic for General and Visceral Surgery, Municipal Hospital DresdenRecruiting
  • Clinic for General, Visceral and Pediatric Surgery, University Hospital DüsseldorfRecruiting
  • Surgical Clinic, University Hospital ErlangenRecruiting
  • Clinic for General, Visceral and Transplant Surgery, University Hospital Frankfurt, Goethe University Frankfurt am MainRecruiting
  • Department for General and Visceral Surgery, Medical Center, University of Freiburg, Faculty of Medicine, University of FreiburgRecruiting
  • Clinic and Polyclinic for General Surgery, Department of Gastrointestinal, Thoracic and Vascular Surgery, University Greifswald, University Hospital GreifswaldRecruiting
  • Clinic for General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Georg-August-UniversityRecruiting
  • University Hospital and Polyclinic for Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale)Recruiting
  • Center for Surgical Medicine - Clinic and Polyclinic for General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf
  • Department of Liver, Bile Duct and Pancreas Surgery, University Department of surgery, Asklepios Klinik BarmbekRecruiting
  • Department of General, Visceral and Transplantation Surgery, University of HeidelbergRecruiting
  • General Visceral and Vascular Surgery, Jena University Medical CenterRecruiting
  • Clinic for Surgery, University Hospital Schleswig-Holstein Lübeck CampusRecruiting
  • University Department of General, Visceral, Vascular and Transplant Surgery, Faculty of Medicine, Otto von Guericke University MagdeburgRecruiting
  • Clinic for General, Visceral and Transplantation Surgery, University Medical Center of the Johannes Gutenberg-University MainzRecruiting
  • Department Hepato-Pancreato-Biliary Surgery, Barmherzige Brüder gGmbH of the Hospital Barmherzige Brüder MunichRecruiting
  • Department of Surgery, University Hospital rechts der IsarRecruiting
  • Clinic for General, Visceral and Transplant Surgery, University of MünsterRecruiting
  • University Hospital for General and Visceral Surgery, Oldenburg HospitalRecruiting
  • Department of General, Visceral and Transplant Surgery, University of Tübingen, Comprehensive Cancer CenterRecruiting
  • Clinic for General and Visceral Surgery, Ulm University Medical CenterRecruiting
  • General and Visceral Surgery, Helios University Medical Center Wuppertal, University Witten/HerdeckeRecruiting
  • Department for General, Visceral, Transplant, Vascular and Pediatric Surgery, Julius-Maximilian-University Würzburg, University Hospital WürzburgRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

A - Anatomical resection

B - Non-anatomical resection

Arm Description

removal of the entire, tumor-bearing liver segment(s)

metastasectomy with a margin of healthy liver tissue irrespective of segmental borders

Outcomes

Primary Outcome Measures

Intrahepatic disease-free survival (iDFS)
Time from operation date to date of disease recurrence in the liver, followed up at intervals of three months for a maximum duration of 24 months or until death. Any new, solid lesion in the liver after resection of all CRLM that fulfils imaging criteria (CT, MRI) of a metastasis is counted as an iDFS event.

Secondary Outcome Measures

Assessment of additional oncological and perioperative outcomes: Intraoperative blood loss [mL]
Intraoperative blood loss presents the amount of blood lost from skin incision until skin closure. Spilling water and ascites will be subtracted. Swabs will be squeezed and their content will also be sucked and added to the fluid collected in the suction containers.
Assessment of additional oncological and perioperative outcomes: Operating time [min]
Time from skin incision until placement of last skin staple/suture.
Assessment of additional oncological and perioperative outcomes: Transfusion of blood, transfused packed red blood cells (PRBC), fresh frozen plasma (FFP) and / or platelet concentrate (PC) [units]
Administration of blood transfusions is documented for the intra- and postoperative period within 48 hours postoperatively.
Assessment of additional oncological and perioperative outcomes: Duration of postoperative hospital stay [days]
Postoperative day 1 until day of discharge
Assessment of additional oncological and perioperative outcomes: Duration of postoperative intermediate/intensive care unit stay [days]
Days on the intermediate care unit (IMC) or intensive care unit (ICU) after surgery. Patient's stay in the recovery room exceeding 24 hours is counted as ICU stay
Assessment of additional oncological and perioperative outcomes: Frequency of peri-operative morbidity after resection
Frequency of peri-operative complications after resection of the primary tumor
Assessment of additional oncological and perioperative outcomes: Kind of peri-operative morbidity after resection
Kind of peri-operative complications after resection of the primary tumor
Assessment of additional oncological and perioperative outcomes: 90-day mortality
Death due to any cause within 90 days after surgery
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Platelet count
Platelet count will be measured preoperatively and on postoperative day 5
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Alanine-aminotransferase
Levels of alanine-aminotransferase (ALT) will be measured preoperatively and on postoperative day 5
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: aspartate-aminotransferase
Levels of aspartate-aminotransferase (AST) will be measured preoperatively and on postoperative day 5
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Gamma-glutamyl transferase
Levels of Gamma-glutamyl transferase (GGT) will be measured preoperatively and on postoperative day 5
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: International normalized ratio
Levels of international normalized ratio (INR) will be measured preoperatively and on postoperative day 5
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Total bilirubin
Levels of total bilirubin will be measured preoperatively and on postoperative day 5
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Albumin
Levels of albumin will be measured preoperatively and on postoperative day 5
Assessment of additional oncological and perioperative outcomes: Frequency invasive re-interventions
Invasive re-interventions such as placement of interventional drains, Endoscopic retrograde cholangiopancreatography (ERCP) with stent placement, chest tube placement, and re-laparotomy within 30 days after the index operation or during patients' initial hospital stay
Assessment of additional oncological and perioperative outcomes: Kind of invasive re-interventions
Invasive re-interventions such as placement of interventional drains, Endoscopic retrograde cholangiopancreatography (ERCP) with stent placement, chest tube placement, and re-laparotomy within 30 days after the index operation or during patients' initial hospital stay
Assessment of additional oncological and perioperative outcomes: Number of patients with positive resection margins
Detection of tumor at the resection margin will be counted as positive resection margin
Assessment of additional oncological and perioperative outcomes: Frequency of Overall survival (OS)
The overall survival of all patients is assessed between operation date to date of death of any cause
Assessment of additional oncological and perioperative outcomes: Frequency of cancer-specific survival (CSS)
The cancer-specific survival of all patients is assessed between operation date to date of death of colorectal cancer
Assessment of additional oncological and perioperative outcomes: Frequency of disease-free survival (DFS)
The disease-free survival of all patients is assessed from operation date to the date of either progressive or recurrent disease, or death of any cause
Assessment of additional oncological and perioperative outcomes: Administration of adjuvant therapy [y/n]
Adjuvant therapy is not recommended. However, the decision for adjuvant therapy is left at discretion of the local oncologist. The administration of adjuvant therapy and kind of chemotherapy protocols used will be documented for both groups.
Assessment of additional oncological and perioperative outcomes: Frequency of oncological Re-interventions [y/n]
Frequency of interventions for treatment of intra- and/or extrahepatic disease recurrence will be documented. These interventions include: Chemotherapy, Surgical resection, Local ablation (e.g. radiofrequency or microwave ablation, stereotactic irradiation), Selective internal radiotherapy (SIRT), other
Assessment of additional oncological and perioperative outcomes: Kind of oncological Re-interventions [y/n]
Kind of interventions for treatment of intra- and/or extrahepatic disease recurrence will be documented. These interventions include: Chemotherapy, Surgical resection, Local ablation (e.g. radiofrequency or microwave ablation, stereotactic irradiation), Selective internal radiotherapy (SIRT), other
Assessment of additional oncological and perioperative outcomes: Assessment of "Quality of life" (QoL)
Quality of life is measured preoperatively and at 90 days (± 7 days) and 12 months (± 7 days) postoperatively using the EORTC QLQ-C30 questionnaire (European Organisation for Research and Treatment of Cancer; Questionnaire for the assessment of Quality of Life of Cancer patients with the module dedicated to colorectal liver metastases (EORTC QLQ-LMC21); the questionnaire assesses multi-item scales, each item scoring from 1 to 4, a high score represents a high level of symptomatology or problems.

Full Information

First Posted
October 30, 2020
Last Updated
October 17, 2023
Sponsor
Technische Universität Dresden
Collaborators
KKS Dresden, German Cancer Research Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04678583
Brief Title
Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
Acronym
ARMANI
Official Title
Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Technische Universität Dresden
Collaborators
KKS Dresden, German Cancer Research Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated colorectal liver metastasis (CRLM).
Detailed Description
Despite increasing application and success of personalized treatment in medical oncology, little progress has been made in personalized surgical cancer therapy. The ARMANI trial presents the first prospective, randomized trial to evaluate effectiveness and safety of molecular-guided resection in patients with colorectal liver metastasis (CRLM). While CRLM might be removed independently of the liver's segmental borders, retrospective data favor anatomic resections in the subgroup of patients with a mutation in the RAS oncogene. Therefore, the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated CRLM. The trial will be carried out among 11 high-volume centers of hepato-biliary surgery in Germany. A total of 220 patients will be enrolled and randomized in a 1:1 ratio to undergo an AR vs. NAR. The primary endpoint is intrahepatic disease-free survival (iDFS). In addition, the study will provide important data on perioperative outcomes and quality of life for both surgical techniques. Given the trend among liver surgeons to aim for parenchymal-sparing operations to preserve liver parenchyma, a positive trial will be practice changing and present the first piece of high-level evidence on benefits of personalized surgical therapy guided by the tumor's mutational profile in patients with CRLM.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Liver Metastasis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, controlled, patient and observer-blinded, confirmatory trial
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A - Anatomical resection
Arm Type
Experimental
Arm Description
removal of the entire, tumor-bearing liver segment(s)
Arm Title
B - Non-anatomical resection
Arm Type
Active Comparator
Arm Description
metastasectomy with a margin of healthy liver tissue irrespective of segmental borders
Intervention Type
Procedure
Intervention Name(s)
Resection of colorectal liver metastases
Intervention Description
Comparison of two liver surgery methods
Primary Outcome Measure Information:
Title
Intrahepatic disease-free survival (iDFS)
Description
Time from operation date to date of disease recurrence in the liver, followed up at intervals of three months for a maximum duration of 24 months or until death. Any new, solid lesion in the liver after resection of all CRLM that fulfils imaging criteria (CT, MRI) of a metastasis is counted as an iDFS event.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Assessment of additional oncological and perioperative outcomes: Intraoperative blood loss [mL]
Description
Intraoperative blood loss presents the amount of blood lost from skin incision until skin closure. Spilling water and ascites will be subtracted. Swabs will be squeezed and their content will also be sucked and added to the fluid collected in the suction containers.
Time Frame
During surgery
Title
Assessment of additional oncological and perioperative outcomes: Operating time [min]
Description
Time from skin incision until placement of last skin staple/suture.
Time Frame
During surgery
Title
Assessment of additional oncological and perioperative outcomes: Transfusion of blood, transfused packed red blood cells (PRBC), fresh frozen plasma (FFP) and / or platelet concentrate (PC) [units]
Description
Administration of blood transfusions is documented for the intra- and postoperative period within 48 hours postoperatively.
Time Frame
48 hours after surgery
Title
Assessment of additional oncological and perioperative outcomes: Duration of postoperative hospital stay [days]
Description
Postoperative day 1 until day of discharge
Time Frame
At day of discharge, assessed up to 90 days
Title
Assessment of additional oncological and perioperative outcomes: Duration of postoperative intermediate/intensive care unit stay [days]
Description
Days on the intermediate care unit (IMC) or intensive care unit (ICU) after surgery. Patient's stay in the recovery room exceeding 24 hours is counted as ICU stay
Time Frame
At day of discharge, assessed up to 90 days
Title
Assessment of additional oncological and perioperative outcomes: Frequency of peri-operative morbidity after resection
Description
Frequency of peri-operative complications after resection of the primary tumor
Time Frame
90 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Kind of peri-operative morbidity after resection
Description
Kind of peri-operative complications after resection of the primary tumor
Time Frame
90 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: 90-day mortality
Description
Death due to any cause within 90 days after surgery
Time Frame
90 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Platelet count
Description
Platelet count will be measured preoperatively and on postoperative day 5
Time Frame
pre-operatively, 5 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Alanine-aminotransferase
Description
Levels of alanine-aminotransferase (ALT) will be measured preoperatively and on postoperative day 5
Time Frame
pre-operatively, 5 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: aspartate-aminotransferase
Description
Levels of aspartate-aminotransferase (AST) will be measured preoperatively and on postoperative day 5
Time Frame
pre-operatively, 5 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Gamma-glutamyl transferase
Description
Levels of Gamma-glutamyl transferase (GGT) will be measured preoperatively and on postoperative day 5
Time Frame
pre-operatively, 5 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: International normalized ratio
Description
Levels of international normalized ratio (INR) will be measured preoperatively and on postoperative day 5
Time Frame
pre-operatively, 5 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Total bilirubin
Description
Levels of total bilirubin will be measured preoperatively and on postoperative day 5
Time Frame
pre-operatively, 5 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Liver biochemical tests: Albumin
Description
Levels of albumin will be measured preoperatively and on postoperative day 5
Time Frame
pre-operatively, 5 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Frequency invasive re-interventions
Description
Invasive re-interventions such as placement of interventional drains, Endoscopic retrograde cholangiopancreatography (ERCP) with stent placement, chest tube placement, and re-laparotomy within 30 days after the index operation or during patients' initial hospital stay
Time Frame
30 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Kind of invasive re-interventions
Description
Invasive re-interventions such as placement of interventional drains, Endoscopic retrograde cholangiopancreatography (ERCP) with stent placement, chest tube placement, and re-laparotomy within 30 days after the index operation or during patients' initial hospital stay
Time Frame
30 days after surgery
Title
Assessment of additional oncological and perioperative outcomes: Number of patients with positive resection margins
Description
Detection of tumor at the resection margin will be counted as positive resection margin
Time Frame
During surgery
Title
Assessment of additional oncological and perioperative outcomes: Frequency of Overall survival (OS)
Description
The overall survival of all patients is assessed between operation date to date of death of any cause
Time Frame
24 month
Title
Assessment of additional oncological and perioperative outcomes: Frequency of cancer-specific survival (CSS)
Description
The cancer-specific survival of all patients is assessed between operation date to date of death of colorectal cancer
Time Frame
24 months
Title
Assessment of additional oncological and perioperative outcomes: Frequency of disease-free survival (DFS)
Description
The disease-free survival of all patients is assessed from operation date to the date of either progressive or recurrent disease, or death of any cause
Time Frame
24 month
Title
Assessment of additional oncological and perioperative outcomes: Administration of adjuvant therapy [y/n]
Description
Adjuvant therapy is not recommended. However, the decision for adjuvant therapy is left at discretion of the local oncologist. The administration of adjuvant therapy and kind of chemotherapy protocols used will be documented for both groups.
Time Frame
24 month
Title
Assessment of additional oncological and perioperative outcomes: Frequency of oncological Re-interventions [y/n]
Description
Frequency of interventions for treatment of intra- and/or extrahepatic disease recurrence will be documented. These interventions include: Chemotherapy, Surgical resection, Local ablation (e.g. radiofrequency or microwave ablation, stereotactic irradiation), Selective internal radiotherapy (SIRT), other
Time Frame
24 month
Title
Assessment of additional oncological and perioperative outcomes: Kind of oncological Re-interventions [y/n]
Description
Kind of interventions for treatment of intra- and/or extrahepatic disease recurrence will be documented. These interventions include: Chemotherapy, Surgical resection, Local ablation (e.g. radiofrequency or microwave ablation, stereotactic irradiation), Selective internal radiotherapy (SIRT), other
Time Frame
24 month
Title
Assessment of additional oncological and perioperative outcomes: Assessment of "Quality of life" (QoL)
Description
Quality of life is measured preoperatively and at 90 days (± 7 days) and 12 months (± 7 days) postoperatively using the EORTC QLQ-C30 questionnaire (European Organisation for Research and Treatment of Cancer; Questionnaire for the assessment of Quality of Life of Cancer patients with the module dedicated to colorectal liver metastases (EORTC QLQ-LMC21); the questionnaire assesses multi-item scales, each item scoring from 1 to 4, a high score represents a high level of symptomatology or problems.
Time Frame
12 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Colorectal cancer with RAS mutation (KRAS or NRAS) Colorectal liver metastases (single or multiple) Planned R0 resection of liver metastases (and primary tumor, if present) Anatomical and non-anatomical liver resection technically feasible Male and female patients, age ≥ 18 years Written informed consent Exclusion Criteria: Extrahepatic metastases Planned staged liver resection (e.g. two-stage hepatectomy) Diagnosis of another cancer < 5 years prior to randomization Exceptions: curatively treated in situ cervical cancer, curatively resected non-melanoma skin cancer Expected lack of compliance Addiction or other illnesses which do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jürgen Weitz, Prof Dr med
Phone
+49-(0)351 458 4850
Email
juergen.weitz@ukdd.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jürgen Weitz, Prof Dr med
Organizational Affiliation
Department of Gastrointestinal-, Thoracic and Vascular Surgery, University Hospital CGC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nuh Rahbari, Prof Dr med
Organizational Affiliation
Allgemein- und Viszeralchirugie, University Hospital Ulm
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Surgery at the University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University
City
Mannheim
State/Province
Baden-Württemberg
ZIP/Postal Code
68167
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of Gastrointestinal-, Thoracic and Vascular Surgery University Hospital Carl Gustav Carus Technische Universität Dresden
City
Dresden
State/Province
Saxony
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jürgen Weitz, Prof Dr med
First Name & Middle Initial & Last Name & Degree
Secretary
Phone
+49-(0)351 458 4850
Facility Name
Department of General, Visceral and Vascular Surgery, Charité, University Medicine Berlin, Campus Benjamin Franklin Berlin
City
Berlin
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinic and Polyclinic for General, Visceral, Thoracic and Vascular Surgery, University Hospital Bonn
City
Bonn
Country
Germany
Individual Site Status
Recruiting
Facility Name
Surgical Clinic, Municipal Hospital Braunschweig gGmbH
City
Braunschweig
Country
Germany
Individual Site Status
Recruiting
Facility Name
Cancer Center, Helios Amper-Hospital Dachau
City
Dachau
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinic for General and Visceral Surgery, Municipal Hospital Dresden
City
Dresden
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinic for General, Visceral and Pediatric Surgery, University Hospital Düsseldorf
City
Düsseldorf
Country
Germany
Individual Site Status
Recruiting
Facility Name
Surgical Clinic, University Hospital Erlangen
City
Erlangen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinic for General, Visceral and Transplant Surgery, University Hospital Frankfurt, Goethe University Frankfurt am Main
City
Frankfurt
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department for General and Visceral Surgery, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg
City
Freiburg
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinic and Polyclinic for General Surgery, Department of Gastrointestinal, Thoracic and Vascular Surgery, University Greifswald, University Hospital Greifswald
City
Greifswald
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinic for General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Georg-August-University
City
Göttingen
Country
Germany
Individual Site Status
Recruiting
Facility Name
University Hospital and Polyclinic for Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale)
City
Halle (Saale)
Country
Germany
Individual Site Status
Recruiting
Facility Name
Center for Surgical Medicine - Clinic and Polyclinic for General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf
City
Hamburg
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Department of Liver, Bile Duct and Pancreas Surgery, University Department of surgery, Asklepios Klinik Barmbek
City
Hamburg
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of General, Visceral and Transplantation Surgery, University of Heidelberg
City
Heidelberg
Country
Germany
Individual Site Status
Recruiting
Facility Name
General Visceral and Vascular Surgery, Jena University Medical Center
City
Jena
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinic for Surgery, University Hospital Schleswig-Holstein Lübeck Campus
City
Lübeck
Country
Germany
Individual Site Status
Recruiting
Facility Name
University Department of General, Visceral, Vascular and Transplant Surgery, Faculty of Medicine, Otto von Guericke University Magdeburg
City
Magdeburg
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinic for General, Visceral and Transplantation Surgery, University Medical Center of the Johannes Gutenberg-University Mainz
City
Mainz
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department Hepato-Pancreato-Biliary Surgery, Barmherzige Brüder gGmbH of the Hospital Barmherzige Brüder Munich
City
München
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of Surgery, University Hospital rechts der Isar
City
München
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinic for General, Visceral and Transplant Surgery, University of Münster
City
Münster
Country
Germany
Individual Site Status
Recruiting
Facility Name
University Hospital for General and Visceral Surgery, Oldenburg Hospital
City
Oldenburg
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of General, Visceral and Transplant Surgery, University of Tübingen, Comprehensive Cancer Center
City
Tübingen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Clinic for General and Visceral Surgery, Ulm University Medical Center
City
Ulm
Country
Germany
Individual Site Status
Recruiting
Facility Name
General and Visceral Surgery, Helios University Medical Center Wuppertal, University Witten/Herdecke
City
Wuppertal
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department for General, Visceral, Transplant, Vascular and Pediatric Surgery, Julius-Maximilian-University Würzburg, University Hospital Würzburg
City
Würzburg
Country
Germany
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer

We'll reach out to this number within 24 hrs